On Tuesday, Innate Immunotherapeutics released a report outlining the first set of results from their Phase 2b trial on the use of their compound, MIS416, in people with secondary progressive multiple...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkValues & Standards
